Brokerages Set Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) PT at $62.17

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned an average rating of “Hold” from the seven research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $62.1667.

A number of research firms have issued reports on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,250 shares of the firm’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total value of $359,600.00. Following the sale, the vice president directly owned 17,044 shares in the company, valued at $845,382.40. This trade represents a 29.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.80% of the stock is owned by company insiders.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. Sit Investment Associates Inc. lifted its position in Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 250 shares in the last quarter. Summit Global Investments lifted its position in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 256 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in Supernus Pharmaceuticals by 3.6% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock worth $415,000 after purchasing an additional 290 shares during the last quarter.

Supernus Pharmaceuticals Stock Down 2.5%

Shares of SUPN opened at $44.41 on Wednesday. The company’s fifty day moving average is $48.68 and its 200-day moving average is $49.53. Supernus Pharmaceuticals has a 12 month low of $30.83 and a 12 month high of $59.68. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -87.08, a price-to-earnings-growth ratio of 0.97 and a beta of 0.55.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.